Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis
- PMID: 11508441
- DOI: 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis
Abstract
Objective: To develop criteria for symptomatic improvement in patients with ankylosing spondylitis (AS), using outcome domain data from placebo-controlled clinical trials of nonsteroidal antiinflammatory drugs (NSAIDs).
Methods: Patient data from 5 short-term, randomized, controlled trials were used to assess equivalence, reliability, and responsiveness of multiple items in the 5 outcome domains for AS treatment: physical function, pain, spinal mobility, patient global assessment, and inflammation. At least one measure per domain was responsive (standardized response mean of > 0.5), except for the spinal mobility domain, which was omitted from the criteria. We developed and tested candidate improvement criteria in a random two-thirds subset from the 3 largest trials and used the remaining one-third for validation. These 3 largest trials included 923 patients (631 receiving NSAIDs, 292 in placebo groups). We selected the multiple domain definition that best distinguished NSAID treatment from placebo by chi-square test and that had a placebo response rate of < or = 25%.
Results: Candidate definitions were changes in single domains and in multiple measure indices, as well as combinations of improvements in multiple domains. Worsening in a domain was defined as a change for the worse of > or = 20% and a net change for the worse of > or = 10 units on a scale of 0-100. Partial remission (for comparison purposes) was defined as an end-of-trial value of < 20/100 in each of the 4 domains. Among 20 candidate criteria, change of > or = 20% and > or = 10 units in each of 3 domains and absence of worsening in the fourth discriminated best in the development subset (51% of patients improved with NSAIDs, 25% with placebo; chi2 = 36.4, P < 0.001). Results were confirmed in the validation subset. Almost all patients satisfying the definition of partial disease remission at the end of the trial had also improved by this criterion. Among all 923 patients, improvement rates using this criterion were 49% for NSAID-treated patients and 24% for placebo-treated patients.
Conclusion: Although further validation using data from new trials is still needed, we conclude that we have developed a clinically valid, easy-to-use measure of short-term improvement in AS.
Comment in
-
Response criteria and criteria for clinically important improvement: separate and equal?Arthritis Rheum. 2001 Aug;44(8):1728-9. doi: 10.1002/1529-0131(200108)44:8<1728::AID-ART306>3.0.CO;2-J. Arthritis Rheum. 2001. PMID: 11508421 No abstract available.
Similar articles
-
Preliminary development of a responder index for chronic low back pain.J Rheumatol. 2007 Jun;34(6):1386-91. J Rheumatol. 2007. PMID: 17552065
-
Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy.Best Pract Res Clin Rheumatol. 2006 Jun;20(3):539-57. doi: 10.1016/j.berh.2006.03.003. Best Pract Res Clin Rheumatol. 2006. PMID: 16777581 Review.
-
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).Arthritis Rheum. 2005 Feb;52(2):582-91. doi: 10.1002/art.20852. Arthritis Rheum. 2005. PMID: 15692973 Clinical Trial.
-
Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis.Ann Rheum Dis. 2004 Nov;63(11):1438-44. doi: 10.1136/ard.2003.016717. Epub 2004 Mar 25. Ann Rheum Dis. 2004. PMID: 15044211 Free PMC article.
-
Outcome variables in ankylosing spondylitis: evaluation of their relevance and discriminant capacity.J Rheumatol. 1999 Apr;26(4):975-9. J Rheumatol. 1999. PMID: 10229431 Clinical Trial.
Cited by
-
Molecular Profiling of Axial Spondyloarthritis Patients Reveals an Association between Innate and Adaptive Cell Populations and Therapeutic Response to Tumor Necrosis Factor Inhibitors.Biomolecules. 2024 Mar 21;14(3):382. doi: 10.3390/biom14030382. Biomolecules. 2024. PMID: 38540800 Free PMC article.
-
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study.RMD Open. 2024 Feb 29;10(1):e003942. doi: 10.1136/rmdopen-2023-003942. RMD Open. 2024. PMID: 38428974 Free PMC article.
-
Six-Month Follow-Up of Periodontal Condition in Rheumatoid Arthritis and Ankylosing Spondylitis Arthritis Patients Undergoing Anti-Tumour Necrosis Factor-α Therapy.J Clin Med. 2024 Jan 13;13(2):448. doi: 10.3390/jcm13020448. J Clin Med. 2024. PMID: 38256582 Free PMC article.
-
Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.Rheumatology (Oxford). 2024 May 2;63(5):1195-1205. doi: 10.1093/rheumatology/kead598. Rheumatology (Oxford). 2024. PMID: 37947318 Free PMC article.
-
Predictors of treatment failure of non-steroidal anti-inflammatory drugs in patients with axial spondyloarthritis with focus on haptoglobin, haptoglobin polymorphism and zonulin.Rheumatol Int. 2024 Mar;44(3):483-495. doi: 10.1007/s00296-023-05484-2. Epub 2023 Oct 17. Rheumatol Int. 2024. PMID: 37847388
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials